Viscosupplementation Market size was over USD 4.78 billion in 2024 and is set to reach USD 14.96 billion by the end of 2037, growing at around 9.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of viscosupplementation is assessed at USD 5.13 billion. The growth of the market can be attributed to the escalating prevalence of osteoarthritis across the globe, owing to the shift of the population towards unhealthy lifestyles and consumption of processed food which in turn is expected to foster arthritis cases. Arthritis is a condition in which people get swelling or inflammation in joints and more than 100 conditions are described by arthritis that affects tissues around joints and other tissues connected to it. For instance, in 2019, there were approximately 526.90 million osteoarthritides (OA) occurrences worldwide. The healthcare provider injects hyaluronic acid into the joints during viscosupplementation treatment to reduce swelling and any sort of pain in the joints.
Osteoarthritis patients have lower levels of hyaluronic acid in their joints, which causes pain. Therefore, a proper infusion of hyaluronic acid delivers optimum results in the elasticity of knee cartilage. It was observed in clinical research that, hyaluronic acid (HA) is a widely known high molecular weight natural glycosaminoglycan consisting of repeating units of D-glucuronic acid and N-acetylglucosamine disaccharide linked by biopolymer B-(1-4) and B-(1-3) glycosides. HA promotes cartilage matrix synthesis and improves cartilage elasticity and humidity. Several orthotic devices, casts, and splints are also utilized to treat the condition of osteoarthritis. It also prevents chondrocyte apoptosis and increases proteoglycan synthesis. As a result, HA is essential for avoiding cartilage erosion and reducing synovial inflammation. In OA patients, the rate of depolymerization and clearance of endogenous HA in joints is higher than normal, which lessens not only the density and molecular weight of HA but also the elastic viscosity of the synovial fluid.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
9.1% |
|
Base Year Market Size (2024) |
USD 4.78 billion |
|
Forecast Year Market Size (2037) |
USD 14.96 billion |
|
Regional Scope |
|
Application (Knee Osteoarthritis, Shoulder Osteoarthritis, Hip Osteoarthritis)
The global viscosupplementation market is segmented and analyzed for demand and supply by application into knee osteoarthritis, shoulder osteoarthritis, hip osteoarthritis, and others. Out of these types of applications, the knee osteoarthritis segment is estimated to gain the largest market share over the projected time frame. The growth of the segment can be attributed to the notably growing prevalence of knee osteoarthritis in people with unhealthy lifestyles across the globe and a rising geriatric population that are prone to knee problems. It was observed that, in 2019, knee osteoarthritis accounted for approximately 60.6% of all prevalent cases globally. Knee osteoarthritis is associated with cartilage breakdown which makes bones rub together. It can be caused by obesity, injuries, and infections. Sports injuries cause a notable number of knee osteoarthritis and other reason such as infections generally cause these issues in people aged above 45. For instance, it was observed that around 3 million children receive sports injuries every year across the globe.
Product (Single Injection, Three Injections, Five Injections)
The global viscosupplementation market is also segmented and analyzed for demand and supply by-products into single injection, three injection, and five injections. Amongst these three segments, the five injections segment is expected to garner a significant share. The segment is expected to grow since it is observed that patients require 5 injections per week to relieve the pain in the joints. Viscosupplementation treatment is reserved until no other option can relieve the pain in joints. The series of injections are repeated every 6 months. As of 2021, the viscosupplementation treatment expenditure was evaluated to be approximately USD 250 million globally. Furthermore, three injection segment is also projected to witness noteworthy growth over the forecast period. Every knee therapy requires 3 weekly injections of hylan G-F 20. For instance, gel and cortisone injections are some of the types of VS therapy injections.
Our in-depth analysis of the global viscosupplementation market includes the following segments:
|
By Product |
|
|
By Application |
|
|
By Source |
|
|
By End-User |
|
North America Market Forecast
The North American viscosupplementation market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2037. The growth of the market can be attributed majorly to the increasing geriatric population, escalating preference for short treatment schedules, and the growing occurrence of osteoarthritis in the region. According to the data released by the Centers for Disease Control and Prevention, by 2020, more than 32.5 million adults in the United States had osteoarthritis. Furthermore, it was also projected that more than 95 million Americans are living with knee pain and require VS therapies to cure the pain, and more than 25%, summing up to 58 million people, in the United States have arthritis. It is stated that knee pain is the 2nd leading pain to cause of chronic pain in people. For instance, knee pain also affects around 22% of adults in the region. Therefore, viscosupplementation treatment is highly required in the region since arthritis increases work disability. For instance, the cost of Medicare and lost earnings in the region are projected to be around USD 300 billion every year in this region. Hence, all these factors are anticipated to expand the viscosupplementation market size in the region over the forecast period.
Asia Pacific Market Forecast
Furthermore, the viscosupplementation market is also expected to obtain notable growth in the Asia Pacific region of the back higher prevalence of arthritis backed by the significant growth in the geriatric population. For instance, approximately 400 million people in Asia were expected to be aged above 65 in 2020, while China and India accounted for 1 billion each. The number of geriatrics in the region was projected to near 18% higher than in the USA. Geriatrics suffer from severe knee problems. Therefore, this factor is expected to boost the growth of the market in the region over the forecast period.
Chugai Pharmaceutical Co., Ltd. has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for its osteoporosis treatment Edirol Tablets 0.5 g/0.75 g (generic name: eldecalcitol, hereafter, Edirol Tablet), a vitamin D3 derivative developed by Chugai based on long-standing research into vitamin D.
Seikagaku Corporation launched HyLink, an intra-articular single-injection viscosupplement for the treatment of knee osteoarthritis in Taiwan, through TCM Biotech International Corp. The main ingredient of HyLink is a cross-linked hyaluronate hydrogel derived from Seikagaku's crosslinking technology.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?